Navigation Links
DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Date:9/26/2007

Multinational Trial to Evaluate Safety, Efficacy of Novel Cortisol

Inhibitor

SAN FRANCISCO, Sept. 26 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that it has begun dosing patients in a Phase 2b clinical trial of DIO-902, a novel cortisol synthesis inhibitor being studied for the treatment of type 2 diabetes mellitus (T2DM).

The Phase 2b multinational trial is a randomized, placebo-controlled, double-blinded study designed to evaluate the safety and efficacy of DIO-902 and to determine dosing for pivotal Phase 3 clinical studies. The primary efficacy endpoint being evaluated is the change in HbA1c, a key measurement of glycemic control, compared to placebo. Secondary endpoints include the change in total and LDL-cholesterol, and the change in blood pressure. Top line data from the trial is expected by the second half of 2008.

"The rollout of this multinational, multicenter trial demonstrates DiObex's ability to launch a major clinical program for the treatment of metabolic disease," CEO David Cory said. "With treatments for both type 1 and type 2 diabetes in mid-stage clinical study and additional indications under evaluation for DIO-902, DiObex is well positioned to move a strong pipeline of product candidates into the advanced stages of development."

The trial is being conducted at 20 centers across the United States, Australia and New Zealand. Approximately 200 patients will be treated for 16 weeks. Patients who are already on a stable dose of metformin will be randomized to receive placebo or one of three doses of DIO-902 once daily for 16 weeks, with the option of continuing on an open label extension for an additional six months of treatment.

Preclinical and clinical studies have suggested that a link exists between high cortisol levels and visceral adiposity, insulin resistance
'/>"/>

SOURCE DiObex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
2. Diobex Announces Successful Completion of Phase 2a Trial Of DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SAN DIEGO , Aug. 29, 2014 /PRNewswire/ ... an emerging biopharmaceutical company, announced today that Santosh ... will be leaving the Company, for personal reasons, ... the Chief Medical Officer of Aires Pharmaceuticals, which ... Vetticaden,s former responsibilities as the Company,s interim Chief ...
(Date:8/29/2014)... 2014 Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... Stanley Global Healthcare Conference on Wednesday, September 10. ... Executive Officer, will provide an update on the company, ... Pacific Daylight Time).   A webcast of ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... and WALTHAM, Mass., May 25, 2011 Interleukin Genetics, Inc. ... USP Hospitales now offers the innovative Heart Health Genetic ... Hospitales, the flagship hospital in Madrid, and will soon ... identifies single nucleotide variations in two Interleukin-1 (IL-1) genes ...
... May 25, 2011 Cambridge Temperature Concepts (CTC), ... has been awarded an I Award by the Wireless-Life ... to solving healthcare challenges . DuoFertility uses wireless technology to ... a baby the best possible chance of conceiving naturally. News ...
Cached Medicine Technology:USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 2USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 3USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 4Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility 2Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility 3Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility 4
(Date:8/29/2014)... Angeles, CA (PRWEB) August 29, 2014 ... inspired others who talked about introducing these cutting ... experience as chairman of the FUE Research Committee has ... studies that redefine what is possible with modern technology. ... of a variety of FUE devices that facilitate extraction ...
(Date:8/29/2014)... 2014 According to a CNN article, ... (8/25), a new study found that those states ... seen a significant decrease in the number of painkiller ... ten year period, and comparing various states with and ... that there was about a 25% decrease in painkiller ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by ... Monitoring For Drug Abuse Trends , Outbreaks (8/20), the National ... attempt to monitor drug abuse trends by turning to social ... drug abuse trends, it is also working with the University ... National Drug Early Warning System, which will be funded by ...
(Date:8/29/2014)... An article entitled How Genes, Gender and ... explains how genes, gender and the environment that an individual ... drugs. Researchers at Indiana University are taking another look at ... and are applying this factor to what is known about ... family and community ties can help to reduce a man’s ...
(Date:8/29/2014)... 29, 2014 Healthpointe is proud to ... Dr. Rodas will be practicing out of Healthpointe’s newest ... member of Healthpointe’s orthopedic team, Dr. Rodas ... and board-certified in occupational medicine. , Among Dr. ... Medical Director of Raytheon, the world-class defense and aerospace ...
Breaking Medicine News(10 mins):Health News:Parsa Mohebi M.D., Beverly Hills Hair Restoration Surgeon Gives Inspiring Lecture on Groundbreaking Techniques in Follicular Unit Extraction 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 3Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Substance Abuse Likelihood Affected by Environment, Gender and Genes 2Health News:Substance Abuse Likelihood Affected by Environment, Gender and Genes 3Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2
... in necessary prescriptions, study finds , , TUESDAY, Feb. 3 ... "doughnut hole" in the Medicare Part D drug plan ... with an employer-based plan, a new study finds. , ... costs from hospitalizations and doctor visits resulting from this ...
... Ala. Exposure to second-hand smoke and alcohol significantly ... at the University of Alabama at Birmingham (UAB). , ... and alcohol are worse for health as a combination, ... an associate professor in the UAB Department of Environmental ...
... Group, Inc.,(NYSE Alternext US: QGP) ( www.QuantumMD.com ) announced ... debut at the 2009 Pri-Med,South Conference and Expo alongside ... Quantum believes PWeR is the next generation in healthcare ... Obama is calling for within,the industry. Pete Martinez, ...
... A thesis from the Sahlgrenska Academy, University of Gothenburg, ... suicide attempt are five times more likely to attempt ... nightmares. , The study included 165 patients aged ... psychiatric departments following a suicide attempt in Sweden. Psychiatric ...
... Feb. 3 Physicians have been raving about the ... 2008 survey of U.S. VASER Lipo physicians, 95% of ... physician or facility. The VASER Lipo System ... contouring applications from precise sculpting to significant fat removal."Hundreds ...
... improve writing skills for those with aphasia with the aid ... doctoral thesis from the Sahlgrenska Academy at the University of ... use spoken language, and the ability to read and write. ... writing aids in the study on which speech and language ...
Cached Medicine News:Health News:Medicare Drug Plan 'Doughnut Hole' Could Impact Seniors' Health 2Health News:Tobacco smoke and alcohol harm liver worse as combo 2Health News:PWeR(TM) Introduced at Regional Healthcare Conference 2Health News:PWeR(TM) Introduced at Regional Healthcare Conference 3Health News:PWeR(TM) Introduced at Regional Healthcare Conference 4Health News:Nightmares increase risk of further suicide attempts 2Health News:THE RESULTS ARE IN! VASER(R) Lipo Receives 95% Approval Rating by Physician Users 2Health News:Computerized writing aids make writing easier for persons with aphasia 2
... segment surgical procedures. For dissection of vitreoretinal ... luer lock tubing set is attached to ... - .02in (.50mm); OD - .06in (1.5mm) ... viscoelastic fluids. 30G (.30mm) tip, flattened. Angled ...
Product designed specifically for posteror segment surgical procedures. Facilitates posterior segment infusion. Flexible tubing 10in (25cm)....
For surgical treatment, repair and irrigation of the nasolacrimal system. Silicone tubing. Length 14in (35cm) ID: .012in (.30mm) OD: .025in (.60mm)...
...
Medicine Products: